Back to Agenda
Session 1: Effectiveness of RMMs: Challenges and Opportunities
Session Chair(s)
Maarten Lagendijk, MSc
Deputy EU QPPV
MSD, Netherlands
Katarzyna Okrojek-Swiderek, MPharm, RPh
Scientific Director, Safety Evaluation Risk Management (SERM)
GlaxoSmithKline, Poland
This session will delve into the challenges and opportunities around effectiveness of Risk Minimisation Measures, with a focus on evolving regulatory expectations and practical methodologies. We will explore updates to GVP Module XVI, examine commonly used approaches such as drug utilisation studies and PASS studies, and reflect on lessons learned from industry and academic experience, including impact studies conducted per PRAC requests. Discussion will also address the real-world impact of RMMs in clinical practice, the objectives we aim to achieve, and the challenges posed by personal data protection and other regulatory requirements. Join us as we unpack the complexities of evaluating RMM effectiveness and work toward improving patient safety outcomes.
Speaker(s)
Setting the Scene: RWE for effectiveness measures in RMMs
Liana Martirosyan
Medicines Evaluation Board (MEB), Netherlands
PRAC Member and PRAC Vice-Chair
Updates to Module XVI: Challenges of Effectiveness Measurement
Mark Perrott, PhD
Axian Consulting Ltd., United Kingdom
Managing Partner
Have an account?